The use of Enduracin--a prolonged-action form of nicotinic acid--in correcting atherogenic dyslipidemias
Oganov, R.G.; Kiseleva, N.G.; Aronov, D.M.; Akhmedzhanov, N.M.; Olfer'ev, A.M.; Kiseleva, N.S.; Perova, N.V.
Kardiologiia 33(10): 54-59; 6
1993
ISSN/ISBN: 0022-9040 PMID: 8139175 Document Number: 407335
The hypolipidemic effects of induracin, a new long-acting nicotinic acid dosage form based on the waxy matrix, and its tolerance were studied in 31 patients with Types IIa and IIb hyperlipoproteinemias in a 6-month blind crossover study. There were decreases in the levels of total cholesterol by 9-13% and low density lipoprotein cholesterol by 12-22%, an increase in high density lipoprotein cholesterol by 12-15%, and a good dynamics in the ratio of blood lipid-transport proteins--a 12-16% increase to the levels of apoprotein AI to a 29% decrease in those of apoprotein B. The drug is well tolerated by patients and may be recommended for correction of atherogenic dyslipidemias.